

LAW OFFICES
LEYDIG, VOIT & MAYER, LTD.
TWO PRUDENTIAL PLAZA, SUITE 4900
CHICAGO, ILLINOIS 60601-6780

TELEPHONE: (312) 616-5600

TELECOPY: (312) 616-5700 (G3)
(312) 849-0495 (G4)**FACSIMILE COVER SHEET**

DATE: OCTOBER 11, 2002

NUMBER OF PAGES (INCLUDING
THIS TRANSMITTAL COVER SHEET): 3

TIME:

AGENT REFERENCE: 635202 (LVM 175912)

FROM: HEATHER KISSLING
REGISTRATION No. 45,790DIRECT LINE: (312) 616-5600
FAX NUMBER: (312) 616-5700TO: EXAMINER J. PARKIN
GROUP ART UNIT: 1648
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C.CV-N (101 AA)
- Rich app 120

TELEPHONE NUMBER: (703) 308-2227

FACSIMILE NUMBER: (703) 308-4426

In re Application of: Boyd

Application No. 09/427,873

Filed: October 27, 1999

For: METHODS OF USING CYANOVIRINS TO INHIBIT VIRAL INFECTION

GROUP ART UNIT: 1648

EXAMINER: PARKIN, J.

MESSAGE:

APPLICANT'S REPRESENTATIVES, CAROL LARCHER AND HEATHER KISSLING, REQUEST A TELEPHONIC INTERVIEW ON THURSDAY (OCTOBER 17) AT 4 PM (EASTERN). PLEASE CALL TO CONFIRM THAT THIS TIME IS CONVENIENT FOR YOU TO DISCUSS THE ISSUES IN THE OUTSTANDING OFFICE ACTION AND THE PROPOSED CLAIM AMENDMENTS. THANK YOU.

A confirmation copy of the transmitted document will:

☒ Not be sent. This will be the only form of delivery of the transmitted document.

The information contained in this facsimile transmission is intended only for the use of the individual or entity named above and those properly entitled to access to the information and may contain information that is privileged, confidential, and/or exempt from disclosure under applicable law. If the reader of this transmission is not the intended or an authorized recipient, you are hereby notified that any unauthorized distribution, dissemination, or duplication of this transmission is prohibited. If you have received this transmission in error, please immediately notify us by telephone or facsimile. Thank you.

DRAFT AMENDMENT FOR DISCUSSION PURPOSES ONLY
NOT FOR INCLUSION IN FILE

In re Application of: Boyd

Application No. 09/427,873

Filed: October 27, 1999

For: METHOD OF USING CYANOVIRINS TO INHIBIT VIRAL INFECTION

Attorney Docket No. 175912

Examiner: Parkin, J.

Art Unit: 1648

Applicants' representatives hereby request a telephonic interview on Thursday, October 17, at 4 PM (EST) to discuss the issues set forth in the outstanding Office Action and the claim amendments proposed below.

PROPOSED AMENDMENT

*Does the address
therapeutic use*

20. (Twice Amended) A method of inhibiting [therapeutically or prophylactically a viral infection of] binding of an enveloped virus to a cell in a host, which method comprises administering to the host an antiviral effective amount of an isolated and purified antiviral agent selected from the group consisting of an antiviral protein, an antiviral peptide, an antiviral protein conjugate, and an antiviral peptide conjugate, wherein said antiviral protein or antiviral peptide has an amino acid sequence of SEQ ID NO: 2 or [a mutant] an antiviral fragment thereof comprising at least nine contiguous amino acids of SEQ ID NO: 2 whereupon administration of said antiviral effective amount of said antiviral agent, [said viral infection of said host] binding of the enveloped virus to the cell is inhibited.

2) Does

*→ (where dr p14, 115
single, double
+ single mutation
all inhibited*

28. (New) The method of claim 20, wherein the antiviral protein conjugate or the antiviral peptide conjugate comprises (i) an amino acid sequence of SEQ ID NO: 2 or an antiviral fragment thereof comprising at least nine contiguous amino acids of SEQ ID NO: 2, and (ii) a virus.

29. (New) The method of claim 28, wherein the virus is a retrovirus.

30. (New) The method of claim 29, wherein the retrovirus is an immunodeficiency virus.

31. (New) The method of claim 30, wherein the immunodeficiency virus is HIV-1 or HIV-2.

CV-N : HIV -
 H5N1 -
 Ebola -

CV-N = CWD -

]- INTERPRETED ALL 3, BOUND TO VIRAL GP

DRAFT